A new stone medicine, enbep, won the China Industrial award and will carry out clinical trials in the United States

The "enbip" product China Industrial award is the highest award in China's industrial field approved and established by the State Council It represents the direction, road and spirit of China's industrialization and the highest level of industrial development It is known as the "Oscar" of China's industry The award is awarded every three years So far, Sinopharm is the only enterprise in Hebei Province that has won this award, and also the only pharmaceutical enterprise that has won this award in previous selections As the third national first-class new drug independently researched and developed in China and the first innovative drug acting on multiple pathological links of acute ischemic stroke in the world, enpipu has won the second prize of national science and technology progress with the highest honor in pharmaceutical science and technology achievements, the 1035 major project of the Ministry of science and technology, the major project of the National Natural Science Foundation and the "Tenth Five Year Plan" of the Ministry of science and technology The special science and technology project "modernization of innovative drugs and traditional Chinese medicine" and the national high-tech industrialization demonstration project are mainly supported At present, EBP has exceeded 1 billion yuan in sales revenue for two consecutive years, becoming the first independent innovative drug with sales exceeding 1 billion yuan in China EBP has applied for 34 domestic patents, 20 of which have been authorized EBP has applied for 8 PCT (patent cooperation agreement) patents, which have been authorized in more than 50 countries and regions such as the European Union, the United States, South Korea and Australia, setting a precedent for China's pharmaceutical intellectual property rights to be authorized to developed countries At the same time, the enbip workshop has passed the FDA certification and obtained the official recognition of the highest pharmaceutical standard in the world EBP products also carry out clinical trials in the United States, accelerating the pace of entering the international market In the congratulatory letter, the provincial government said that as a leading enterprise in the pharmaceutical industry, Shijiazhuang Pharmaceutical Group, in recent years, closely around the decision-making and deployment of the provincial Party committee and the provincial government, has continuously increased capital investment and vigorously promoted product innovation and technological transformation New drug research and development ranks the forefront of the national pharmaceutical industry, and the comprehensive strength of enterprises has significantly increased, making a positive contribution to the economic and social development of the province At present, Hebei Province is in the critical period of climbing, transformation and upgrading, and the task of changing the mode and adjusting the structure is very arduous We hope that Sinopharm group will cherish the honor, make further efforts, seize the opportunity and take the responsibility bravely, continue to adhere to the concept of "doing well in medicine and serving China", increase R & D investment, vigorously promote scientific and technological innovation and industrial upgrading, actively explore foreign markets, constantly improve the comprehensive strength of enterprises, and make new and greater contributions to promoting the scientific development and green rise of Hebei Province.